Since the injunction isn't being granted, Glasscock said there's no reason to expedite the rest of the case, which centers on a contractual dispute between the two drug companies.
September 10, 2021 at 04:03 PM
3 minute read
A Japan-based drug manufacturer won’t be required to alter its allocation of a scarce pain treatment drug to fulfill its contracts with an American drug distributor, Vice Chancellor Sam Glasscock III has ruled.
There would have been no way to enforce Takeda Pharmaceuticals’ compliance with an injunction requested by AbbVie Endocrine Inc., Glasscock wrote in a post-trial opinion.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Sam Glasscock.
